Confident Interval News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Confident Interval. Real-time updates on events, politics, business and more.

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

June 4, 2022

04.06.2022 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, presented today new and updated results from the CARTITUDE ...

United States New Jersey Hemophagocytic Lymphohistiocytosis Saadz Usmani Ying Huang Janssen Biotech Inc

Source: wallstreet-online.de

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtag

June 4, 2022

28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meetingOverall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reachedResul...

United States Hemophagocytic Lymphohistiocytosis Saadz Usmani Joanne Choi Ying Huang Biotech Corporation

Source: pharmiweb.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Confident Interval News Today

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtag

Explore More Categories